The Rotterdam School

Ab Osterhaus

Osterhaus built the Rotterdam school and trained its most consequential alumni. He later became the subject of the Dutch "eel affair" — advising the WHO on influenza vaccination policy while holding a commercial interest in influenza vaccines through Viroclinics Biosciences. The pattern established by the mentor would recur across his students' careers: undisclosed conflicts of interest at the intersection of public health guidance and commercial benefit.

Ron Fouchier

Fouchier achieved international prominence — and significant controversy — by engineering H5N1 avian influenza to become transmissible via aerosol between ferrets, the animal model closest to human respiratory transmission. The work triggered a global moratorium debate and drew direct comparison to the gain-of-function research that would later feature in the COVID-19 origins investigation.

On 1 February 2020, Fouchier was present on a teleconference convened by Anthony Fauci, Francis Collins, and Jeremy Farrar. The subject was the emerging SARS-CoV-2 virus and the draft of what would become the most cited paper in the origins debate: The Proximal Origin of SARS-CoV-2. Fouchier and Koopmans were invited by Farrar but declined authorship credit because, according to one author, they "opposed scientific articles considering the lab leak theory at all." Their undisclosed contributions were later confirmed via FOIA requests and congressional hearings.

Marion Koopmans

Koopmans received an early draft of Proximal Origin on 8 February 2020, one week after the teleconference. She joined the WHO COVID-19 origins team in 2021, the team that declared laboratory origin "extremely unlikely" without gaining access to the primary patient data from Wuhan — the same data that Rogier Louwen and I have since obtained and analyzed.

As a member of WHO's Scientific Advisory Group for the Origins of SARS-CoV-2 (SAGO), Koopmans never disclosed or formally investigated: the DEFUSE proposal's furin cleavage site insertion methodology, Baric's congressional testimony confirming FCS insertion in live viruses, the Zhou Yusen military vaccine patent filed 24 February 2020, or the Ben Hu / PREDICT-2 funding chain that terminated in the months before the outbreak. These are not obscure findings. They are in the congressional record and in publicly available grant databases.

Erasmus MC — through Koopmans and Fouchier — sat at the center of the network that produced all of these connections. The absence of any SAGO investigation into them is documented and unaddressed.

Vincent Munster

Munster's research portfolio at Rocky Mountain Laboratories covered filoviruses, henipaviruses, bat coronavirus ecology, and transmissibility studies — precisely the intersection of pathogen types that appear in the PRJNA605983 dataset (H7N9, Nipah, SARS-CoV-2) that Rogier Louwen and I analyzed.

Munster was a named partner in the DEFUSE proposal submitted to DARPA on 30 January 2018 by Peter Daszak (EcoHealth Alliance), Ralph Baric (UNC Chapel Hill), Shi Zhengli (Wuhan Institute of Virology), Ian Lipkin (Columbia University), and Duke-NUS. DEFUSE proposed creating chimeric bat coronaviruses with enhanced human infectivity and explicitly discussed inserting furin cleavage sites into the spike protein. DARPA rejected the proposal. The research appears to have continued without DARPA funding. Munster's participation was confirmed in a 2024 letter from Senator Rand Paul to NIH Director Bertagnolli.

Emmie de Wit

De Wit's laboratory at Rocky Mountain Laboratories published the rhesus macaque study that became the primary scientific basis for the FDA Emergency Use Authorization of remdesivir (Nature 2020, 585:558–560, DOI: 10.1038/s41586-020-2423-5). The paper demonstrated remdesivir efficacy against SARS-CoV-2 in the non-human primate model.

What the paper did not disclose: RML had a pre-pandemic long-standing collaboration with Gilead Sciences — the manufacturer of remdesivir. This collaboration was not listed as a conflict of interest in the published paper. The FDA EUA was issued in May 2020, based substantially on this data. Gilead subsequently earned billions in revenue from remdesivir contracts with governments worldwide.

An Emergency Use Authorization can only be issued when no adequate, approved, and available alternative treatment exists. The simultaneous active suppression of hydroxychloroquine — through the RECOVERY trial's toxic dosing protocol and through regulatory action — was the mechanism that kept that legal threshold met. The financial and regulatory logic is coherent.

ODNI Declassification — 18 June 2026

The ODNI declassification released 391 pages of intelligence community assessments on SARS-CoV-2 origins. The documents confirm that Lawrence Livermore National Laboratory assessed laboratory origin as equally plausible as natural spillover in May 2020 — a finding that was suppressed and remained classified for six years. Whistleblowers described career threats for those who considered or documented laboratory origin scenarios. The suppression operated across multiple agencies simultaneously.

Anthony Fauci, as NIAID Director, was the institutional supervisor of both Munster and de Wit at Rocky Mountain Laboratories. The oversight structure that ran the gain-of-function research network, provided the remdesivir EUA data, and controlled the intelligence assessments on origins was concentrated in the same organizational hierarchy.

Vincent Munster — Federal Charges

On 25 January 2026, Munster was detained at Detroit Metropolitan Airport carrying 113 vials of mpox samples from an active outbreak in the Democratic Republic of Congo. The samples had not been declared to customs. A colleague traveling with him was also charged. Federal charges were filed by the Eastern District of Michigan on 2 June 2026.

The case is active. The significance in this context is not the outcome — it is the behavioral pattern it represents: a senior BSL-4 researcher, trained in Rotterdam, operating within the same institutional network that ran gain-of-function research and suppressed origins analysis, moving undeclared pathogen samples across international borders from an active outbreak zone. The pattern does not require a conspiracy theory. It requires a question: who provides oversight of this network, and what has that oversight produced?